Immatics (IMTX) Projected to Post Earnings on Thursday

Immatics (NASDAQ:IMTX) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Immatics to post earnings of ($0.03) per share and revenue of $16.16 million for the quarter.

Immatics Stock Performance

Shares of IMTX opened at $4.55 on Thursday. Immatics has a fifty-two week low of $4.06 and a fifty-two week high of $13.77. The business has a 50-day moving average of $5.35 and a 200 day moving average of $8.00. The firm has a market cap of $543.07 million, a P/E ratio of -6.89 and a beta of 0.83.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. The Goldman Sachs Group upgraded Immatics to a “strong-buy” rating in a research note on Monday, November 25th. Bank of America cut their target price on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 19th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $16.67.

Hedge Funds Weigh In On Immatics

An institutional investor recently raised its position in Immatics stock. Bank of America Corp DE lifted its position in shares of Immatics (NASDAQ:IMTX) by 166.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,575 shares of the company’s stock after buying an additional 2,231 shares during the period. Bank of America Corp DE’s holdings in Immatics were worth $25,000 as of its most recent SEC filing. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.